Payment overview · 2025
General Payments
$912.19
23 reported records · 9 companies
Healthcare provider profile · identity verified
Jayeshkumar S Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · JERSEY CITY, NJ · NPI 1962509265
Verified facts
What the public records show
CMS Open Payments records show Jayeshkumar S Patel, M.D. received $912.19 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 438 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.98 | 21.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.11 | 16.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.73 | 16.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $145.62 | 16.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.75 | 13.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.03 | 10.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.41 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.34 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $891.97 | 22 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $145.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $129.94 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.75 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $98.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.99 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $69.71 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $69.71 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.69 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 26 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 438 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 243 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 84 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
84 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
438 | 106 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
132 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1437 | 360 |
| Losartan Potassium | Losartan Potassium | 1113 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 1100 | 285 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 937 | 243 |
| Diclofenac Sodium | Diclofenac Sodium | 902 | 253 |
| Pantoprazole Sodium | Pantoprazole Sodium | 778 | 241 |
| Metformin Hcl | Metformin Hcl | 761 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 713 | 156 |
| Eliquis | Apixaban | 699 | 100 |
| Gabapentin | Gabapentin | 529 | 121 |
| Furosemide | Furosemide | 510 | 146 |
| Tamsulosin Hcl | Tamsulosin Hcl | 498 | 112 |
| Alendronate Sodium | Alendronate Sodium | 463 | 129 |
| Clopidogrel | Clopidogrel Bisulfate | 455 | 115 |
| Farxiga | Dapagliflozin Propanediol | 438 | 106 |
| Famotidine | Famotidine | 420 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 418 | 125 |
| Januvia | Sitagliptin Phosphate | 414 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 378 | 130 |
| Carvedilol | Carvedilol | 359 | 91 |
| Divalproex Sodium | Divalproex Sodium | 354 | 47 |
| Montelukast Sodium | Montelukast Sodium | 354 | 116 |
| Metoprolol Tartrate | Metoprolol Tartrate | 328 | 92 |
| Donepezil Hcl | Donepezil Hcl | 325 | 58 |
| Azithromycin | Azithromycin | 312 | 218 |
| Lisinopril | Lisinopril | 308 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 290 | 100 |
| Omeprazole | Omeprazole | 257 | 74 |
| Jardiance | Empagliflozin | 243 | 67 |
| Pioglitazone Hcl | Pioglitazone Hcl | 231 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 223 | 57 |
| Mirtazapine | Mirtazapine | 219 | 39 |
| Glimepiride | Glimepiride | 210 | 55 |
| Levetiracetam | Levetiracetam | 204 | 38 |
| Memantine Hcl | Memantine Hcl | 191 | 28 |
| Finasteride | Finasteride | 180 | 30 |
| Lactulose | Lactulose | 180 | 60 |
| Simvastatin | Simvastatin | 177 | 43 |
| Trazodone Hcl | Trazodone Hcl | 158 | 29 |
| Ketoconazole | Ketoconazole | 155 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 150 | 26 |
| Sertraline Hcl | Sertraline Hcl | 146 | 34 |
| Glipizide Er | Glipizide | 144 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 38 |
| Latanoprost | Latanoprost | 141 | 23 |
| Mupirocin | Mupirocin | 141 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 40 |
| Vascepa | Icosapent Ethyl | 133 | 27 |
| Lokelma | Sodium Zirconium Cyclosilicate | 132 | 35 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 125 | 56 |
| Ezetimibe | Ezetimibe | 121 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 60 |
| Buspirone Hcl | Buspirone Hcl | 115 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 112 | 34 |
| Albuterol Sulfate | Albuterol Sulfate | 111 | 72 |
| Enalapril Maleate | Enalapril Maleate | 107 | 28 |
| Ozempic | Semaglutide | 104 | 26 |
| Tradjenta | Linagliptin | 102 | 17 |
| Atenolol | Atenolol | 101 | 28 |
| Ammonium Lactate | Ammonium Lactate | 99 | 30 |
| Potassium Chloride | Potassium Chloride | 98 | 36 |
| Prednisone | Prednisone | 97 | 47 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 96 | 39 |
| Meclizine Hcl | Meclizine Hcl | 95 | 42 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | 21 |
| Allopurinol | Allopurinol | 85 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 84 | 32 |
| Linzess | Linaclotide | 84 | 28 |
| Ibuprofen | Ibuprofen | 83 | 57 |
| Spironolactone | Spironolactone | 82 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 58 |
| Levofloxacin | Levofloxacin | 80 | 58 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 65 |
| Risperidone | Risperidone | 79 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 79 | 39 |
| Benztropine Mesylate | Benztropine Mesylate | 78 | suppressed |
| Meloxicam | Meloxicam | 78 | 23 |
| Enoxaparin Sodium | Enoxaparin Sodium | 74 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 74 | suppressed |
| Glipizide | Glipizide | 73 | 24 |
| Nifedipine Er | Nifedipine | 71 | 19 |
| Baclofen | Baclofen | 70 | suppressed |
| Entresto | Sacubitril/Valsartan | 70 | 14 |
| Valsartan | Valsartan | 68 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 66 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 24 |
| Repaglinide | Repaglinide | 60 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 21 |
| Insulin Lispro | Insulin Lispro | 57 | 17 |
| Rybelsus | Semaglutide | 57 | 13 |
| Ranolazine Er | Ranolazine | 56 | 13 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Nystatin | Nystatin | 54 | 24 |
| Silver Sulfadiazine | Silver Sulfadiazine | 54 | 24 |
| Brilinta | Ticagrelor | 52 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 51 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Lidocaine | Lidocaine | 49 | 13 |
| Loperamide | Loperamide Hcl | 47 | 26 |
| Restasis | Cyclosporine | 46 | 12 |
| Alprazolam | Alprazolam | 45 | 12 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 19 |
| Hydrocortisone | Hydrocortisone | 43 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 19 |
| Enulose | Lactulose | 41 | 14 |
| Lorazepam | Lorazepam | 41 | 12 |
| Naproxen | Naproxen | 41 | 19 |
| Sodium Chloride | 0.9 % Sodium Chloride | 41 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Gemfibrozil | Gemfibrozil | 39 | 11 |
| Megestrol Acetate | Megestrol Acetate | 39 | 22 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Lumigan | Bimatoprost | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | 12 |
| Midodrine Hcl | Midodrine Hcl | 35 | 13 |
| Tramadol Hcl | Tramadol Hcl | 35 | 21 |
| Xarelto | Rivaroxaban | 35 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 34 | suppressed |
| Cilostazol | Cilostazol | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 19 |
| Methimazole | Methimazole | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 30 |
| Trulance | Plecanatide | 34 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 16 |
| Scopolamine | Scopolamine | 33 | suppressed |
| Torsemide | Torsemide | 33 | 15 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Santyl | Collagenase Clostridium Hist. | 32 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 31 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Alogliptin | Alogliptin Benzoate | 28 | 15 |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Proctozone-Hc | Hydrocortisone | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Meropenem | Meropenem | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | 12 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | 14 |
| Humalog | Insulin Lispro | 20 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Mefloquine Hcl | Mefloquine Hcl | 19 | 18 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Clozapine | Clozapine | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Nystop | Nystatin | 17 | 12 |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Atropine Sulfate | Atropine Sulfate | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Prolia | Denosumab | 13 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $912.19 · 23 records | AstraZeneca Pharmaceuticals LP | CAPLYTA, CREON, EVENITY, FARXIGA, FASENRA, JARDIANCE, Kerendia, Korlym, LINZESS, OTEZLA, REPATHA, VOQUEZNA, VRAYLAR, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error